Applied Genetic Technologies (AGTC) Prices 6.5M Share Common Offering at $5/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Applied Genetic Technologies Corp. (AGTC) PT Raised to $10 at Chardan Capital Markets
February 6, 2020 12:10 PM ESTChardan Capital Markets analyst Gbola Amusa raised the price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to $10.00 (from $7.50) while maintaining a Buy rating.
... MorePre-Open Stock Movers 02/06: (UIS) (FSCT) (LDOS) Higher (TNXP) (RWLK) (FNKO) Lower (more...)
February 6, 2020 9:24 AM ESTPre-Open Stock Movers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 56.5% LOWER; announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD) following an unblinded, pre-specified interim analysis by the Independent Data Monitoring Committee (IDMC). Based on interim analysis results of the first 50% of enrolled participants, the IDMC recommended stopping the trial for futility as Tonmya is unlikely to demonstrate a statistically significant improvement in the... More
After-Hours Stock Movers 02/05: (SONO) (ELF) (ZNGA) Higher; (TNXP) (FNKO) (GPRO) Lower (more...)
February 5, 2020 6:00 PM ESTAfter-Hours Movers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) 64.7% LOWER; announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD) following an unblinded, pre-specified interim analysis by the Independent Data Monitoring Committee (IDMC). Based on interim analysis results of the first 50% of enrolled participants, the IDMC recommended stopping the trial for futility as Tonmya is unlikely to demonstrate a statistically significant improvement in the primary... More
Applied Genetic Technologies (AGTC) Announces Proposed 6M Share Public Offering of Common Stock
February 5, 2020 4:37 PM ESTApplied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All the shares in the offering will be sold by AGTC. In addition, AGTC expects to grant the underwriters a 30-day option to purchase up to... More
